百普赛斯公告，公司已于2026年1月26日向香港联合交易所有限公司递交了发行境外上市股份(H股)并在 香港联交所主板挂牌上市的申请，并于同日在香港联交所网站刊登了本次发行上市的申请资料。 ...

鉴于本次发行上市的认购对象将仅限于符合相关条件的境外投资者及依据 中国相关法律法规有权进行境外证券投资的境内合格投资者，公司将不会在境内 证券交易所的网站和符合境内监管机构规定条件的媒体上刊登该申请资料，但为 使境内投资者及时了解该等申请资料披露的本次发行上市以及公司的其他相关 信息，现提供该申请资料在香港联交所网站的查询链接供查阅： 证券代码：301080 证券简称：百普赛斯 公告编号：2026-002 北京百普赛斯生物科技股份有限公司 关于向香港联交所递交境外上市股份(H 股)发行上市申请 并刊发申请资料的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京百普赛斯生物科技股份有限公司（以下简称"公司"）已于 2026 年 1 月 26 日向香港联合交易所有限公司（以下简称"香港联交所"）递交了发行境 外上市股份（H 股）并在香港联交所主板挂牌上市（以下简称"本次发行上市"） 的申请，并于同日在香港联交所网站刊登了本次发行上市的申请资料。 该申请材料为公司按照香港证券及期货事务监察委员会（以下简称"香港证 监会"）及香港联交所的要求编制和刊发，为草拟 ...

Company Overview - Beijing Baipusi Biotechnology Co., Ltd. (Baipusi) has submitted its listing application to the Hong Kong Stock Exchange, with CMB International as its sole sponsor [1] - Baipusi is a leading player in the biological reagent industry, particularly in the recombinant protein segment, ranking first among domestic suppliers in China and third globally by revenue in 2024 [1][3] - The company offers a comprehensive product portfolio that includes high-quality biological reagents and various technical services, supporting the entire value chain of biopharmaceutical companies from R&D to clinical applications [3][5] Financial Performance - For the fiscal year 2023, Baipusi reported revenues of approximately RMB 544 million, with projected revenues of RMB 645 million for 2024 and RMB 613 million for the nine months ending September 30, 2025 [6][10] - The gross profit for 2023 was around RMB 459 million, with a gross margin of 84.3%, and is expected to maintain a gross margin of approximately 82.2% in 2025 [8][10] - The company recorded a profit of approximately RMB 148 million for 2023, with a projected profit of RMB 132 million for the nine months ending September 30, 2025 [10][11] Market Overview - The global life sciences tools market reached USD 32.1 billion in 2020 and is projected to grow at a CAGR of 5.2% to USD 39.3 billion by 2024, further expanding to USD 61 billion by 2030 [12] - The biological reagent market, which includes products and services, was valued at USD 18.2 billion in 2020, with expectations to grow to USD 25.1 billion by 2024, and USD 35.6 billion by 2030 [14][16] - The recombinant protein market is anticipated to grow from USD 1 billion in 2020 to USD 3 billion by 2024, with a CAGR of 31.9%, and further to USD 7.8 billion by 2030 [18][19] Business Model - Baipusi operates on a "dual-engine" business model in China and the United States, allowing it to acquire advanced technological knowledge and efficient production capabilities [5] - The company serves a diverse clientele, including the top 20 global pharmaceutical companies and the top five life sciences service providers, with a 100% repurchase rate from its top clients [5][6] - Baipusi's production facilities in Beijing and Suzhou comply with international quality standards, including ISO certifications and GMP [6]

| 编纂 的[编纂]數目 :: | [编纂]股H股(視乎[编纂]行使與否而定) | | --- | --- | | [编纂]數目 : | [编纂]股H股(可予重新分配) | | [编纂]數目 : | [編纂]股H股(可予重新分配及視乎[編纂]行使與否 | | | 定) | | 最高[編纂] : 每股H股[编纂]港元,另加1.0%經紀佣金、0.0027% | | | | 證監會交易徵費、0.00565%的聯交所交易費以 | | | 及0.00015%的會財局交易徵費(須於申請時以港 | | | 元繳足,可予退還) | | 面值 | 每股H股人民幣1.00元 | | 股份代號 : [·] | | 智通财经APP获悉，据港交所1月26日披露，北京百普赛斯生物科技股份有限公司(简称：百普赛斯， 301080.SZ)向港交所主板递交上市申请书，招商证券国际为其独家保荐人。招股书显示，百普赛斯是全 球生命科学工具及技术服务提供商，致力于赋能生物制药公司覆盖研发、生产及临床应用的全价值链。 根据弗若斯特沙利文的资料，在全球重组蛋白市场中，按2024年收入计，公司在所有中国本土供应商中 排名第一，在全球所有供应商中排名第三。 ...

智通财经APP获悉，据港交所1月26日披露，北京百普赛斯生物科技股份有限公司(简称：百普赛斯， 301080.SZ)向港交所主板递交上市申请书，招商证券国际为其独家保荐人。招股书显示，百普赛斯是全 球生命科学工具及技术服务提供商，致力于赋能生物制药公司覆盖研发、生产及临床应用的全价值链。 根据弗若斯特沙利文的资料，在全球重组蛋白市场中，按2024年收入计，公司在所有中国本土供应商中 排名第一，在全球所有供应商中排名第三。 | ■纂]的[编纂]數目 | .. | [编纂]股H股(視乎[编纂]行使與否而定) | | --- | --- | --- | | [编纂]數目 | ። | [编纂]股H股(可予重新分配) | | [编纂 數目 | .. | [编纂]股H股(可予重新分配及視乎[编纂]行使與否 | | | | 定) | | 成尚[编纂] | | : 每股H股[編纂]港元,另加1.0%經紀佣金、0.0027% | | | | 證監會交易徵費、0.00565%的聯交所交易費以 | | | | 及0.00015%的會財局交易徵費(須於申請時以消 | | | | 元繳足,可予退還) | | 面值 | = | 每股H股 ...

据港交所1月26日披露，北京百普赛斯（301080）生物科技股份有限公司(简称：百普赛斯，301080.SZ) 向港交所主板递交上市申请书，招商证券国际为其独家保荐人。招股书显示，百普赛斯是全球生命科学 工具及技术服务提供商，致力于赋能生物制药公司覆盖研发、生产及临床应用的全价值链。根据弗若斯 特沙利文的资料，在全球重组蛋白市场中，按2024年收入计，公司在所有中国本土供应商中排名第一， 在全球所有供应商中排名第三。 | ■纂的[编纂]數目 | | : [編纂]股H股(視乎[編纂]行使與否而定) | | --- | --- | --- | | [编纂]數目 | .. | [编纂]股H股(可予更新分配) | | [编纂]數目 | .. | [编纂]股H股(可予重新分配及視乎[编纂]行使與否 | | | | 定) | | 取尚编纂1 | .. | 每股H股[編纂]港元,另加1.0%經紀佣金、0.0027% | | | | 證監會交易徵費、0.00565%的聯交所交易費以 | | | | 及0.00015%的會財局交易徵費(須於申請時以港 | | | | 元繳足,可予退還) | | 面值 | .. 每股H股人民幣1 ...

格隆汇1月26日｜据港交所文件，北京百普赛斯生物科技股份有限公司向港交所提交上市申请书。 ...

据港交所文件：北京百普赛斯生物科技股份有限公司向港交所提交上市申请书。 ...

截至1月26日收盘，猴痘概念上涨3.13%，位居概念板块涨幅第8，板块内，50股上涨，凯普生物、迈克 生物、之江生物等20%涨停，达安基因、科华生物等涨停，万孚生物、智飞生物、百普赛斯等涨幅居 前，分别上涨16.23%、14.87%、12.58%。跌幅居前的有谱尼测试、富祥药业、合富中国等，分别下跌 9.72%、5.51%、5.32%。 资金面上看，今日猴痘概念板块获主力资金净流入15.26亿元，其中，46股获主力资金净流入，6股主力 资金净流入超亿元，净流入资金居首的是智飞生物，今日主力资金净流入2.61亿元，净流入资金居前的 还有众生药业、君实生物、达安基因等，主力资金分别净流入2.23亿元、1.69亿元、1.65亿元。 今日涨跌幅居前的概念板块 | 688575 | 亚辉龙 | 1.73 | 2.31 | 1476.63 | 7.35 | | --- | --- | --- | --- | --- | --- | | 300439 | 美康生 | 5.17 | 7.59 | 1457.59 | 6.07 | | | 物 | | | | | | 300482 | 万孚生 | 16.23 | 15.99 | ...

Core Viewpoint - The A-share market shows a slight decline with the Shanghai Composite Index at 4133.16 points, just above the five-day moving average, indicating mixed market sentiment [1]. Group 1: Market Overview - As of 13:59 today, the total trading volume of A-shares reached 27,509.71 billion yuan [1]. - The Shanghai Composite Index experienced a change of -0.07% [1]. Group 2: Stocks Exceeding Five-Day Moving Average - A total of 165 A-shares have surpassed the five-day moving average today [1]. - Notable stocks with significant deviation rates include: - Baipusais (301080) with a deviation rate of 11.09% and a price increase of 14.92% [2]. - Huisheng Biological (300871) with a deviation rate of 10.40% and a price increase of 20.01% [2]. - Sidike (300806) with a deviation rate of 10.20% and a price increase of 14.84% [2]. - Other stocks with smaller deviation rates include: - Qianwei Yangchu (300492) with a deviation rate of 8.33% [2]. - Yuedong Nianqing (301111) with a deviation rate of 7.82% [2]. - Heshun Oil (603353) with a deviation rate of 7.50% [2].